Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial

被引：2

作者：

Popat, S. ^{[1
]}

Kim, H. R. ^{[2
]}

Ahn, M-J. ^{[3
]}

Yang, J. C-H. ^{[4
]}

Han, J-Y. ^{[5
]}

Hochmair, M. J. ^{[6
]}

Lee, K. H. ^{[7
]}

Delmonte, A. ^{[8
]}

Garcia Campelo, M. R. ^{[9
]}

Kim, D-W. ^{[10
]}

Griesinger, F. ^{[11
]}

Felip, E. ^{[12
]}

Califano, R. ^{[13
,14
]}

Spira, A. ^{[15
,16
]}

Gettinger, S. ^{[17
]}

Tiseo, M. ^{[18
]}

Ni, Q. ^{[19
]}

Zhang, P. ^{[20
]}

Camidge, D. R. ^{[21
]}

机构：

[1] Royal Marsden Hosp, Med Oncol, London, England

[2] Yonsei Univ, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr,Coll Med, Seoul, South Korea

[3] Samsung Med Ctr, Hematol Oncol, Seoul, South Korea

[4] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[5] Natl Canc Ctr, Med Oncol, Goyang, South Korea

[6] Krankenhaus Nord, Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria

[7] Chungbuk Natl Univ Hosp, Cheongju, South Korea

[8] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Med Oncol Dept, Meldola, Forli Cesena, Italy

[9] Complejo Hosp Univ A Coruna, Dept Med Oncol, La Coruna, Spain

[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[11] Carl von Ossietzky Univ Oldenburg, Pius Hosp Oldenburg, Hematol & Oncol, Oldenburg, Germany

[12] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

[13] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England

[14] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[15] Virginia Canc Specialists, Res Inst, The Woodlands, TX USA

[16] US Oncol Res, The Woodlands, TX USA

[17] Yale Canc Ctr, Med Oncol, New Haven, CT USA

[18] Univ Hosp Parma, Dept Med Oncol, Parma, Italy

[19] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA

[20] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA

[21] Univ Colorado, Ctr Canc, Med Oncol, Aurora, CO USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1614

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1300P

引用

页码：S840 / S841

页数：2

共 50 条

[1] Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C-H.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A. I.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2018, 29 : 746 - 746
[2] Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
Califano, R.
Hochmair, M. J.
Gridelli, C.
Delmonte, A.
Garcia Campelo, M. R.
Bearz, A.
Griesinger, F.
Morabito, A.
Felip, E.
Ghosh, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2019, 30 : 41 - 41
[3] Systemic and Intracranial Efficacy of Brigatinib vs.Crizotinib: Updated Results from the ALTA-1L Trial
Popat, S.
Kim, H. R.
Ahn, M. -J.
Yang, James C. H.
Han, J. -Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Campelo, M. R. Garcia
Kim, D. -W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S.
Tiseo, M.
Lin, H.
Liu, Y.
Zhang, P.
Camidge, D. R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S8 - S9
[4] Brigatinib vs crizotinib in the phase 3 ALTA-1L trial: Updated results
Griesinger, F.
Kim, H. R.
Ahn, M. -J.
Yang, J. C.
Han, J. -Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D. -W.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S.
Tiseo, M.
Lin, H.
Liu, Y.
Zhang, P.
Popat, S.
Camidge, D. R.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 142 - 142
[5] Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naive ALK plus NSCLC: Final results from ALTA-1L
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S. N.
Tiseo, M.
Lin, H. M.
Liu, Y.
Vranceanu, F.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2021, 32 : S954 - S955
[6] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
Griesinger, Frank
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James Chih-Hsin
Han, Ji Youn
Hochmair, Maximilian
Lee, Hyeong
Delmonte, Angelo
Garcia Compelo, Maria Rosario
Kim, Dong-Wan
Felip, Enriqueta
Califano, Raffaele
Spire, Alexander
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Ni, Quanhong
Zhang, Pingkuan
Popat, Sanjay
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
[7] Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L
Ahn, M-J.
Kim, H. R.
Yang, J. C-H.
Han, J-Y.
Li, J. Y-C.
Hochmair, M. J.
Chang, G-C.
Delmonte, A.
Lee, K. H.
Garcia Campelo, M. R.
Gridelli, C.
Spira, A.
Califano, R.
Griesinger, F.
Ghosh, S.
Felip, E.
Kim, D-W.
Zhang, P.
Popat, S.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2020, 31 : S843 - S844
[8] Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L
Garcia Campelo, M. R.
Zhu, Y.
Lin, H. M.
Perol, M.
Jahanzeb, M.
Popat, S.
Zhang, P.
Goodman, E.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2020, 31 : S844 - S844
[9] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK plus NSCLC from ALTA-1L
Yang, James C. H.
Kim, Hye R.
Ahn, Myung-Ju
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki H.
Delmonte, Angelo
Garcia Campelo, Maria R.
Kim, Dong-Wan
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander
Gettinger, Scott
Tiseo, Marcello
Haney, Jeff
Kerstein, David
Popat, Sanjay
Camidge, D. R.
ANNALS OF ONCOLOGY, 2019, 30
[10] Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.
Ahn, Myung-Ju
Kim, HyeRyun
Yang, James Chih-Hsin
Han, Ji-Youn
Lee, Jong Seok
Hochmair, Maximilian J.
Li, Jacky Yu-Chung
Chang, Gee-Chen
Lee, Ki Hyeong
Gridelli, Cesare
Campelo, Rosario Garcia
Delmonte, Angelo
Kim, Dong-Wan
Kerstein, David
Ni, Quanhong
Zhang, Pingkuan
Popat, Sanjay
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →